Related Experiment Video

Updated: Jun 2, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer

Hiroyuki Yoshida1, Toshiyuki Sumi, Xu Zhi

  • 1Department of Obstetrics and Gynaecology, Osaka City University Graduate School of Medicine, Osaka, 545-8585, Japan. hirogynecol@aol.com

Anticancer Research
|April 22, 2011
PubMed
Abstract

Insights

Claudin-4 inhibition increases cisplatin sensitivity in ovarian cancer cells, suggesting it drives platinum resistance. This protein may be a therapeutic target for chemoresistant ovarian tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Claudin-4, a tight junction protein, is implicated in ovarian cancer development and spread.
  • The specific role of claudin-4 in platinum resistance remains unclear.

Purpose of the Study:

  • To investigate the role of claudin-4 in platinum resistance in ovarian cancer.
  • To determine if claudin-4 influences cisplatin sensitivity and cellular uptake.

Main Methods:

  • Claudin-4 expression was inhibited in ovarian cancer cells to assess cisplatin sensitivity.
  • Fluorescence-labeled cisplatin was used to measure cellular cisplatin accumulation.
  • Claudin-4 expression was evaluated in patient tumor tissues via immunohistochemistry.

Main Results:

  • Inhibiting claudin-4 significantly enhanced cisplatin sensitivity and cellular cisplatin uptake.
  • Higher claudin-4 expression correlated with chemoresistance in ovarian cancer tissues.
  • Patients with claudin-4-positive tumors had shorter overall survival.

Conclusions:

  • Claudin-4 appears to contribute to platinum resistance in ovarian cancer.
  • Claudin-4 represents a potential therapeutic target for platinum-resistant ovarian tumors.

More Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro13:20

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro

Published on: July 17, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...